Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancer

摘要

TMPRSS2:ERG(TE)fusionoccursinapproximately50% ofallprostatecancercases. 1 However,detailsaboutaltered signaling or the difference of gene expression regarding potential therapeutic targets between TE fusion-positive and negative group is yet to be fully investigated. In this study, we investigated the landscape of molecular signal- ing and curated potential therapeutic targets in TE fusion- positive prostate cancers using The Cancer Genome Atlas data. Firstly, we identified 3870 genes in coordination with ERG in RNA expression and nine cancer-related pathways specifically altered in TE fusion-positive prostate cancer patients.Secondly,wededucedrepositionable55drugstar- getingforTEfusion-positiveprostatecancerfromnetwork analysis. Finally, we provided experimental data for six drugsobtainedfromourinsilicoanalysisandshowedsen- sitivity specific for TE fusion-positive prostate cancer cell line.